📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-07-25 12:21
99 analysed today
FollowTelegram
99
Today
151,543
All-time analysed
43,429
Positive
6,735
Negative
92,563
Neutral
8,748
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
2 announcements match the current filters (relevance ≥ 5).
Mercury Laboratories Q1 PAT Rises 26% YoY to ₹1.23 Cr Despite Flat Revenue
Mercury Laboratories reported a marginal 1.2% YoY increase in revenue to ₹18.32 Cr for the quarter ended June 30, 2026. Despite the stagnant top-line, Net Profit grew by 26.8% YoY to ₹1.23 Cr, indicating improved operational efficiency. However, on a sequential basis, revenue declined by 10.4% from ₹20.44 Cr in the preceding March quarter. The company maintained its profitability with an EPS of ₹10.21 for the quarter.
Confidence: HIGH
What changedThe company released its unaudited financial results for Q1 FY2026-27, showing profit growth despite flat revenue.
Why it mattersFor a micro-cap company (₹97 Cr market cap), maintaining profitability in a highly regulated pharmaceutical environment is key, but the lack of top-line growth suggests the company is awaiting new capacity to scale.
Revenue (Q1 FY27): ₹18.32 CrNet Profit (Q1 FY27): ₹1.23 CrYoY PAT Growth: 26.8%QoQ Revenue Growth: -10.4%EPS: ₹10.21
📅 Short termThe stock may see neutral to slightly positive sentiment due to profit growth, though the sequential revenue dip might limit gains.
📈 Long termStructural growth is tied to the successful registration of products in international markets like the Philippines and Africa, and the operationalization of the new Jarod plant.
⚠ Risk flags
- Stagnant YoY revenue growth
- High dependency on regulatory approvals for new products
- Limited pricing power due to NPPA regulations
- High receivables (125 days as per context)
Key Highlights
Revenue from operations stood at ₹18.32 Cr, a slight increase from ₹18.10 Cr in the same quarter last year.
Net Profit for the quarter reached ₹1.23 Cr, up from ₹0.97 Cr in June 2025.
Total expenses were contained at ₹16.77 Cr, representing 91.5% of total income.
Earnings Per Share (EPS) improved to ₹10.21 from ₹8.08 in the year-ago period.
Quarterly revenue represents approximately 24% of the TTM revenue of ₹76 Cr.
👀 What to Watch
Investors should monitor the progress of the new injection manufacturing unit commissioning, which is critical for breaking the current revenue stagnation. Watch for improvements in the 125-day receivable cycle and the impact of NPPA pricing regulations on future margins.
Rs 3.22 Cr Q1 PAT: Mercury Laboratories reports 232% YoY profit growth
Mercury Laboratories reported a robust Q1 FY27 (ending June 2026) with Net Profit surging 232% YoY to Rs 3.22 Cr, up from Rs 0.97 Cr in June 2025. Revenue from operations grew 10% YoY to Rs 19.94 Cr. Profitability was significantly aided by a spike in Other Income to Rs 1.18 Cr (vs Rs 0.17 Cr YoY) and controlled expenditure. The quarterly EPS of Rs 26.84 is a substantial jump from the previous year's Rs 8.08, representing over 60% of the total TTM EPS in a single quarter.
Confidence: HIGH
What changedThe company released its Q1 FY27 financial results, showing a sharp increase in both top-line and bottom-line performance compared to the previous year.
Why it mattersFor a micro-cap company with a Rs 97 Cr market cap, a quarterly profit of Rs 3.22 Cr is highly material, as it represents nearly 64% of its entire TTM Net Profit of Rs 5 Cr.
Revenue (Q1): Rs 19.94 CrNet Profit (Q1): Rs 3.22 CrYoY PAT Growth: 232%Other Income: Rs 1.18 CrQ1 PAT vs TTM PAT: 64.4%
📅 Short termThe stock is likely to react positively in the short term due to the significant earnings beat and high EPS relative to the current stock price.
📈 Long termLong-term value depends on the company's ability to scale its core pharmaceutical formulations and successfully enter new international markets like the Philippines and Africa as planned.
⚠ Risk flags
- Significant portion of profit derived from Other Income
- Regulatory price caps by NPPA limiting pricing power
- High receivables period (125 days) typical of the industry
Key Highlights
Net Profit for the quarter ended June 2026 stood at Rs 3.22 Cr vs Rs 0.97 Cr in the year-ago period
Revenue from operations increased 10% YoY to Rs 19.94 Cr from Rs 18.14 Cr
Other Income rose significantly to Rs 1.18 Cr, contributing approximately 27% to the Profit Before Tax
Quarterly EPS reached Rs 26.84, compared to the full-year FY25 EPS of Rs 26.17
Total expenses were contained at Rs 16.77 Cr despite the increase in operational scale
👀 What to Watch
Investors should monitor the sustainability of these margins in upcoming quarters, specifically checking if the 'Other Income' spike is a one-off event. Additionally, track the progress of the new injection manufacturing unit commissioning mentioned in the company's growth strategy.
